MetaCap

Regeneron Pharmaceuticals Inc. (REGN)

NASDAQ: REGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD

920.69-1.71 (-0.19%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

REGN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$95.24B
EPS (TTM)
$45.24
Dividend yield
0.40% ($3.70)
Ex-dividend date
Nov 20, 2026
52-week range
591.52 – 991.73
Day range
916.66 – 948.42
Volume / Avg
877.67K / 805.45K
Beta
—

52-week range

$591.52$991.73

REGN stock today

On Nov 20, REGN ended the session at $920.69, shedding $1.71 (0.19%), versus the S&P 500's 3.70% decline. At this level, REGN sits near the top of its 52-week range of $591.52 to $991.73: 7.2% below the high, set on Nov 4, 2026 and 55.6% above the low. REGN is up 19.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 21.8%.

At 20.4x trailing earnings, Regeneron Pharmaceuticals trades below the peer-group median of 33.1x. Its forward P/E of 12.8x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Regeneron Pharmaceuticals pays an annual dividend of $3.70 per share, a 0.40% yield at the current price.

Summary generated from market data by MetaCap's automated system. Methodology

About Regeneron Pharmaceuticals

Company profile

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Leonard S. Schleifer M.D., Ph.D.
Headquarters
Tarrytown, NY
Employees
15,410
IPO year
1991

Financial highlights

Full financials

In fiscal 2025, Regeneron Pharmaceuticals generated $14.34 billion in revenue, up 1.0% from fiscal 2024, its 3rd consecutive year of revenue growth. Net income was $4.50 billion (+2.1% year over year), for a net margin of 31.4% versus a median of 35.6% in the prior 5 years. Operating margin was 24.9%.

Regeneron Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$14.34B$14.20B$13.12B$12.17B$16.07B
Growth+0.99%+8.27%+7.76%-24.26%+89.14%
Net income$4.50B$4.41B$3.95B$4.34B$8.08B
EPS (diluted)$41.48$38.34$34.77$38.22$71.97

Analyst forecast

Forecast

Consensus (28 analysts)

buy

Avg. price target

$991.00+7.64%

  • Strong buy 4
  • Buy 15
  • Hold 9
  • Sell 0
  • Strong sell 0

Target range

Low $812.00High $1,175.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 30, 2026
EPS actual vs est.
$18.45 vs $13.76
Surprise
+34.08%

Dividends

Dividend history
Annual dividend
$3.70
Last payment
$0.94
Ex-dividend date
Nov 20, 2026
Pay date
Dec 3, 2026

REGN news

All REGN news

Regeneron Pharmaceuticals peers

Health Care sector
REGN peer companies
CompanyPrice% ChgMarket capCompare
GSKGSK plc ADR47.76-0.13%$95.73Bvs REGN
SNYSanofi ADS46.52+1.00%$111.70Bvs REGN
BMYBristol-Myers Squibb Company58.80+0.79%$120.19Bvs REGN
TAKTakeda Pharmaceutical Company Limited ADR21.77+1.68%$69.55Bvs REGN
VRTXVertex Pharmaceuticals Incorporated515.02-1.08%$130.58Bvs REGN
TEVATeva Pharmaceutical Industries Limited39.23+1.79%$45.77Bvs REGN
ONCBeOne Medicines Ltd. ADR390.94-2.19%$44.66Bvs REGN
RPRXRoyalty Pharma plc Class A68.45+1.08%$39.36Bvs REGN

Indexes, lists and sector

Regeneron Pharmaceuticals stock FAQ

What is Regeneron Pharmaceuticals's stock price today?

REGN last traded at $920.69 as of Nov 20, 4:00 PM EST, down 0.19% on the day. Prices are delayed at least 15 minutes.

Does Regeneron Pharmaceuticals pay a dividend?

Yes. Regeneron Pharmaceuticals pays $3.70 per share annually, a 0.40% yield. The most recent dividend of $0.94 had an ex-dividend date of Nov 20, 2026.

What is REGN's P/E ratio?

REGN trades at a trailing P/E ratio of 20.35 and a forward P/E of 12.85, compared with a median of 33.1 for its closest peers.

Is Regeneron Pharmaceuticals in the S&P 500?

Yes. Regeneron Pharmaceuticals (REGN) is a constituent of the S&P 500 index.

Who is Regeneron Pharmaceuticals's CEO?

Dr. Leonard S. Schleifer M.D., Ph.D. is the chief executive officer of Regeneron Pharmaceuticals Inc., which has about 15,410 employees.

What is the REGN 52-week high?

The 52-week high for REGN is $991.73 and the 52-week low is $591.52. The stock is currently 7.2% below its high.

Compare REGN